N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide

• ChemBase编号: 154839
• 分子式: C15H17N3O2
• 平均质量: 271.31438
• 单一同位素质量: 271.1320768
• SMILES: c1c2c(oc1)cnc(c2)C(=O)N[C@@H]1[C@H]2CCN(C1)CC2
• Canonical SMILES: O=C(c1ncc2c(c1)cco2)N[C@H]1CN2CC[C@H]1CC2
• InChI: InChI=1S/C15H17N3O2/c19-15(12-7-11-3-6-20-14(11)8-16-12)17-13-9-18-4-1-10(13)2-5-18/h3,6-8,10,13H,1-2,4-5,9H2,(H,17,19)/t13-/m0/s1
• InChIKey: IPKZCLGGYKRDES-ZDUSSCGKSA-N

名称和登记号

名称

• IUPAC标准名: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide
• IUPAC传统名: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide
• 别名: N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide; PHA-543613

登记号

• CAS号: 478149-53-0
• PubChem SID: 162248977
• PubChem CID: 9930121

理论计算性质

• Acid pKa: 14.535064
• 质子受体: 3
• 质子供体: 1
• LogD (pH = 5.5): -1.4073635
• LogD (pH = 7.4): 0.29083017
• Log P: 0.7505125
• 摩尔折射率: 74.3156 cm^3
• 极化性: 29.612497 Å^3
• 极化表面积: 58.37 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: DMSO: ≥20 mg/mL
• 外观: white to off-white powder

安全信息

• 德国WGK号: 1
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H319
• GHS警示性声明: P305 + P351 + P338
• 保存温度: room temp

产品相关信息

• 纯度: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C15H17N3O2

详细说明

Sigma Aldrich - PZ0135

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
PHA-543613 is a potent selective α7 nAChR agonist. Nicotinic acetylcholine receptors are ligand-gated ion channels activated by nicotine, expressed in multiple tissues, with high functional expression in brain. The homomeric subtype α7 is a potential therapeutic target for cognitive deficits in schizophrenia and Alzheimer′s disease. PHA-543613 is active in both in vitro (binding, calcium flux, patch-clamp) and in vivo (auditory gating, novel object recognition) assays.